ArticleInvestigational new drugs2015

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.

Jaafar Bennouna et al.PubMed ↗Publisher ↗

No numbers read from the abstract.